- 42 Downloads
In a retrospective, observational study involving 1562 patients (treated with aflibercept between March 2015 and October 2017), 10 patients including one female patient and two male patients [ages not stated; not all sexes stated] were described, who developed scleral nodule, intraocular inflammation, endophthalmitis, central retinal artery occlusion (CRAO), myocardial infarction (MI) or cerebrovascular accident (CVA) while receiving aflibercept, bevacizumab or ranibizumab [not all dosages, durations of treatments to reactions onsets and outcomes stated]. The use of intravitreal aflibercept and bevacizumab was off-label.
Case 1: A male patient, who had neovascular age-related macular degeneration (nAMD), received three ranibizumab injections followed by one intravitreal aflibercept [ziv-aflibercept] 0.05mL (1.25mg) injection as needed. Four days following aflibercept administration, he developed scleral nodule, which resolved following treatment with unspecified antibiotics and...
- Singh SR, et al. Safety of 5914 intravitreal ziv-aflibercept injections. British Journal of Ophthalmology 103: 805-810, No. 6, Jun 2019. Available from: URL: http://doi.org/10.1136/bjophthalmol-2018-312453 - India